glutathione for crohn's Antioxidant Therapy in Inflammatory Bowel Diseases Seeking Health Glutathione Plus Lozenge,

Disclosure of interest: none Poster Session II - RISK FACTORS - PRIMARY AND SECONDAR PREVENTION 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.02 - SECONDARY PREVENTION P1002 - ESOC25-228 PREDIABETES AND DIABETES MELLITUS TYPE 2 ONE YEAR AFTER ACUTE ISCHEMIC STROKE Kurt Mlgg 1,2 , Anel Karisik 1,2 , Lukas Scherer 1,2 , Lucie Buergi 1,2 , Benjamin Dejakum 1 , Silvia Komarek 1 , Julian Granna 2 , Christian Boehme 1 , Raimund Pechlaner 1 , Thomas Tll 1 , Michael Knoflach, Stefan Kiechl 1,2 , Susanne Kaser 3 , Alexander Egger 4 , Andrea Griesmacher 4 , Lukas Mayer-Suess 1 1 Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria, 2 VASCage, Centre on Clinical Stroke Research, Innsbruck, Austria, 3 Department of Internal Medicine I, Medical University of Innsbruck, Innsbruck, Austria, 4 Central Institute of Clinical Chemistry and Laboratory Medicine, Medical University of Innsbruck, Innsbruck, Austria Background and Aims: The evolution of glycemic status in post-stroke patients remains poorly understood, particularly regarding treatments for type II diabetes mellitus (DM II), such as glucagon-like peptide-1 receptor agonists (GLP-1-RA) and sodium-glucose co-transporter 2 (SGLT-2) inhibitors, which have not been studied in an exclusive post-stroke population

In stock Free shipping on orders over $199

Probiotic microorganisms, in Handbook of probiotics and prebiotics

Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing antibodies in mice

The method according to claim 1 or 2, the use according to any one of claims 3-6, or the composition according to claim 7 or 8, wherein the composition further comprises a pharmaceutically acceptable excipient, carrier, or diluent

Recent advances in anti-angiogenic therapy of cancer